Table 1.
Comparison of HPIV patients with no HPIV patients over 3 different time eras
| Transplant Era | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1974-1992 | 1993-2001 | 2002-2010 | |||||||
| Controls n (%) |
HPIV Cases n (%) |
P- value |
Controls n (%) |
HPIV Cases n (%) |
P- value |
Controls n (%) |
HPIV Cases n (%) |
P- value |
|
| N | 1657 | 51 | 1737 | 57 | 1611 | 65 | |||
| Median age | 18.3 | 17.5 | 0.85 | 32.8 | 33.1 | 0.97 | 39.0 | 46.9 | 0.14 |
| Age by range | 0.80 | 0.10 | 0.03 | ||||||
| Age < 10 | 514 (31) | 18 (35) | 424 (24) | 14 (25) | 346 (21) | 8 (12) | |||
| Age 10-19 | 359 (22) | 10 (20) | 224 (13) | 2 (4) | 210 (13) | 4 (6) | |||
| Age ≥ 20 | 784 (47) | 23 (45) | 1089 (63) | 41 (72) | 1055 | 53 (82) | |||
| Male | 977 (59) | 33 (65) | 0.41 | 933 (54) | 36 (63) | 0.16 | 984 (61) | 35 (54) | 0.24 |
| Donor Sex Match | 0.57 | 0.23 | 0.60 | ||||||
| Match | 554 (51) | 16 (46) | 565 (52) | 29 (60) | 488 (43) | 20 (39) | |||
| Mismatch | 540 (49) | 19 (54) | 531 (48) | 19 (40) | 649 (57) | 31 (61) | |||
| Diagnosis category | 0.30 | 0.39 | 0.30 | ||||||
| Lymphoid-malignant | 227 (14) | 4 (8) | 306 (18) | 12 (21) | 401 (25) | 18 (28) | |||
| Myeloid-malignant | 1174 | 36 (71) | 1127 (65) | 32 (56) | 886 (55) | 39 (60) | |||
| Non-malignant | 256 (15) | 11 (22) | 304 (18) | 13 (23) | 324 (20) | 8 (12) | |||
| Autologous | 563 (34) | 16 (32) | 0.70 | 641 (37) | 9 (16) | < 0.01 | 474 (29) | 14 (22) | 0.17 |
| Allogeneic | < 0.01 | 0.76 | 0.32 | ||||||
| UCB | 1 (<1) | 0 (0) | 140 (8) | 7 (13) | 590 (37) | 26 (40) | |||
| Matched sibling | 824 (50) | 19 (37) | 445 (26) | 16 (28) | 359 (22) | 14 (22) | |||
| Other relatives | 67 (4) | 8 (16) | 49 (3) | 3 (5) | 49 (3) | 5 (8) | |||
| Unrelated | 202 (12) | 8 (16) | 462 (27) | 22 (39) | 139 (9) | 6 (9) | |||
| CMV serostatus | 0.30 | 0.84 | 0.61 | ||||||
| R+ | 893 (54) | 33 (65) | 813 (47) | 28 (49) | 859 (53) | 31 (48) | |||
| R−/D− | 608 (37) | 15 (30) | 754 (43) | 22 (39) | 676 (42) | 29 (45) | |||
| R−/D+ | 115 (7) | 2 (4) | 165 (10) | 5 (9) | 69 (4) | 4 (6) | |||
| Unknown | 41 (3) | 1 (2) | 5 (<1) | 2 (4) | 7 (<1) | 1 (2) | |||
| Conditioning Intensity | 0.20 | 0.11 | 0.01 | ||||||
| Myeloablative + TBI | 1266 | 35 (69) | 1225 (71) | 42 (74) | 631 (39) | 23 (35) | |||
| Myeloablative, no | 391 (24) | 16 (31) | 461 (27) | 11 (19) | 529 (33) | 13 (20) | |||
| RIC | 0 (0) | 0 (0) | 49 (3) | 4 (7) | 447 (28) | 29 (45) | |||
| T-depletion | 433 (26) | 20 (39) | 0.04 | 288 (18) | 19 (33) | < 0.01 | 404 (25) | 17 (26) | 0.85 |
P values represent chi square comparisons of characteristics of HPIV infected vs. control patients within each time era.
Abbreviations: CMV, Cytomegalovirus; R, recipient; D, donor; RIC, reduced intensity conditioning; TBI, total body irradiation; UCB, umbilical cord blood